SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer

SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer

Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome

Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome